All Categories

Lilly, Incyte rheumatoid arthritis drug succeeds.

Eli Lilly and Co and Incyte Corp said a third late-stage study of their experimental rheumatoid arthritis drug met its main goal.
The drug, baricitinib, was more effective than the decades-old treatment methotrexate, after 24 weeks of treatment, in reducing signs and symptoms of the inflammatory disorder, the companies said on Tuesday.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button

Adblock Detected

Please consider supporting us by disabling your ad blocker